Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy

被引：1

作者：

Doudoo, Chris Osam ^{[1
,2
]}

Gyekye, Prince Kwabena ^{[2
]}

Emi-Reynolds, Geoffrey ^{[2
]}

Adu, Simon ^{[2
]}

Kpeglo, David Okoh ^{[2
]}

Tagoe, Samuel Nii Adu ^{[3
]}

Agyiri, Kofi ^{[3
]}

机构：

[1] Sweden Ghana Med Ctr, POB MD 1879, Accra, Ghana

[2] Univ Ghana, Sch Nucl & Allied Sci, POB AE 1, Accra, Ghana

[3] Natl Ctr Radiotherapy & Nucl Med, Korle Bu, Accra, Ghana

来源：

JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES | 2023年 / 54卷 / 02期

关键词：

ALARA; Dose optimisation; Electronic dosimeters; Organ doses; Radiotherapy; RADIATION-INDUCED CANCER; BODY-MASS INDEX; 2ND CANCERS; RADIOTHERAPY; SURVIVORS; PROSTATE; THERAPY; ORGANS;

D O I：

10.1016/j.jmir.2023.03.031

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Dose and secondary cancer risk of the breast and thyroid during high dose rate (HDR) brachytherapy for 100 gynaecological cancer patients have been estimated. The organ doses were measured using LiF thermoluminescence dosimeters LiF (TLD-100). Patient demographic data (i.e. age and body mass index (BMI)) were also collected observed for the correlation between age and breast dose; body mass index (BMI) and breast dose as well as BMI and thyroid dose. The average breast dose for cervical, vaginal and endometrial cancers were 7.44, 8.03 and 10.72 mGy, respectively. The average thyroid dose for cervical, vaginal and endometrial cancers were 2.32, 2.95 and 3.02 mGy, respectively. Excess absolute risk of the breast increased with atat exposure. It is recommended to intensify post-treatment follow-ups and optimize the doses to the breast and thyroid.

引用

页码：335 / 342

页数：8

共 48 条

[1] American Cancer Society, 2016, TREATM OPT CERV CANC
[2] American Cancer Society, 2020, Second Cancer Related to Treatment
[3] [Anonymous], 2017, CANC FACTS FIG
[4] [Anonymous], 2006, Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2, DOI [10.17226/11340, DOI 10.17226/11340]
[5] Brachytherapy in the treatment of cervical cancer: a review
Banerjee, Robyn
Kamrava, Mitchell
[J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2014, 6 : 555 - 564
[6] Body mass index, dose to organs at risk during vaginal brachytherapy, and the role of three-dimensional CT-based treatment planning
Boyle, John M.
Craciunescu, Oana
Steffey, Beverley
Cai, Jing
Chino, Junzo
[J]. BRACHYTHERAPY, 2014, 13 (04) : 332 - 336
[7] Centre of Disease Control and Prevention (CDCP), 2019, WHAT IS GYN CANC
[8] Second cancers among 104,760 survivors of cervical cancer:: Evaluation of long-term risk
Chaturvedi, Anil K.
Engels, Eric A.
Gilbert, Ethel S.
Chen, Bingshu E.
Storm, Hans
Lynch, Charles F.
Hall, Per
Langmark, Froydis
Pukkala, Eero
Kaijser, Magnus
Andersson, Michael
Fossa, Sophie D.
Joensuu, Heikki
Boice, John D.
Kleinerman, Ruth A.
Travis, Lois B.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (21): : 1634 - 1643
[9] Second cancers after radiotherapy: update and recommandations
Cosset, J. -M.
Hetnal, M.
Chargari, C.
[J]. RADIOPROTECTION, 2018, 53 (02) : 101 - 105
[10] Dandapani Savita V, 2015, ScientificWorldJournal, V2015, P483208, DOI 10.1155/2015/483208

← 1 2 3 4 5 →